Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients

OBJECTIVE: This study investigated whether pyrosequencing can be used to determine the methylation status of the MGMT promoter as a clinical biomarker using relatively old archival tissue samples of glioblastoma. We also examined other prognostic factors for survival of glioblastoma patients. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Cheol, Kim, Ki Uk, Kim, Young Zoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Neurosurgical Society 2016
Materias:
Clinical Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754584/
https://www.ncbi.nlm.nih.gov/pubmed/26885283
http://dx.doi.org/10.3340/jkns.2016.59.1.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754584/
https://www.ncbi.nlm.nih.gov/pubmed/26885283
http://dx.doi.org/10.3340/jkns.2016.59.1.26

Ejemplares similares